In December 2021, sugemalimab was approved in China for the first-line treatment of epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) negative metastatic NSCLC administered in combination with pemetrexed and carboplatin for nonsquamous NSCLC (Dhillon and Duggan, 2022). This evidence concerns the gene ALK and non-small cell lung carcinoma.